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Introduction {#jgh312248-sec-0005}
============

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cause of cancer‐related mortalities.[1](#jgh312248-bib-0001){ref-type="ref"} Within South Africa (SA), it is the fourth most commonly diagnosed cancer, being the second most common among males and the fourth most common among females and the sixth leading cause of cancer mortalities in SA.[1](#jgh312248-bib-0001){ref-type="ref"}, [2](#jgh312248-bib-0002){ref-type="ref"} Male and female ratios have remained constant (53--55% *vs* 45--47%, respectively).[2](#jgh312248-bib-0002){ref-type="ref"}, [3](#jgh312248-bib-0003){ref-type="ref"}, [4](#jgh312248-bib-0004){ref-type="ref"}, [5](#jgh312248-bib-0005){ref-type="ref"}, [6](#jgh312248-bib-0006){ref-type="ref"} Male patients have a 1.27 estimated lifetime risk of developing CRC, and females have a lower risk of 0.75.[6](#jgh312248-bib-0006){ref-type="ref"} CRC incidence rates within SA have progressively increased over the years, with the annual crude incidence in SA CRC male and female patients in 2014 reported as 7.34 and 5.86 per 100 000, respectively.[6](#jgh312248-bib-0006){ref-type="ref"} CRC occurs mostly within the white (Caucasian) population group in SA patients (52--54%), followed by black (African) (26--28%), colored (mixed ancestry) (14--15%), and Asian (Indian) patients (4--7%).[2](#jgh312248-bib-0002){ref-type="ref"}, [3](#jgh312248-bib-0003){ref-type="ref"}, [4](#jgh312248-bib-0004){ref-type="ref"}, [5](#jgh312248-bib-0005){ref-type="ref"}, [6](#jgh312248-bib-0006){ref-type="ref"} The pathogenesis of CRC is complex and diverse and is influenced by multiple factors, including diet, lifestyle, and genetic predispositions. It is reported that the white patient population group in SA appears to follow the classic Western trend, which presents at a later age, having an association with diet and lifestyle factors, although the molecular pathology has not been extensively investigated.[7](#jgh312248-bib-0007){ref-type="ref"}, [8](#jgh312248-bib-0008){ref-type="ref"} Comparatively, the black SA population has a higher frequency of young (\<50 years) CRC patients, possibly because of diet and lifestyle changes either due to urbanization or a familial contribution.[7](#jgh312248-bib-0007){ref-type="ref"}, [8](#jgh312248-bib-0008){ref-type="ref"}, [9](#jgh312248-bib-0009){ref-type="ref"} A study by Prodehl *et al*. showed that 49.0% of SA CRC patients reported a family history of cancer, with CRC the most frequently diagnosed, where maternal (35%) and fraternal (33%) members were the most affected, followed by paternal members (25%).[10](#jgh312248-bib-0010){ref-type="ref"}

High prevalence rates for young CRC patients, \<40 years of age, have been reported globally, with the lowest rates found in the United States, Europe, and New Zealand (1--6%) and the highest in Asian and Middle Eastern countries (10--39%).[11](#jgh312248-bib-0011){ref-type="ref"}, [12](#jgh312248-bib-0012){ref-type="ref"}, [13](#jgh312248-bib-0013){ref-type="ref"} The current SA National Cancer Registry (NCR) statistics, spanning a 5‐year period (2010--2014), show that young CRC patients, under 50 years of age, contribute an average of 18% of all CRC cases, of which approximately 7% were younger than 40 years of age.[2](#jgh312248-bib-0002){ref-type="ref"}, [3](#jgh312248-bib-0003){ref-type="ref"}, [4](#jgh312248-bib-0004){ref-type="ref"}, [5](#jgh312248-bib-0005){ref-type="ref"}, [6](#jgh312248-bib-0006){ref-type="ref"} The NCR 2014 report also showed an exponential growth in CRC incidence in male patients from 2010 to 2014. A correlation between race and age was also demonstrated as the majority of young patients younger than 50 years old were black (32%) *versus* white patients (11%) (*P* \< 0.0001) (NCR 2013--2014).[5](#jgh312248-bib-0005){ref-type="ref"}, [6](#jgh312248-bib-0006){ref-type="ref"} The burden of disease in SA has also been a challenge to assess due to underreporting of CRC cases as registries are mainly limited to small urban areas.[14](#jgh312248-bib-0014){ref-type="ref"}

Thus, this descriptive epidemiological study will serve as a preliminary study to obtain a greater understanding of the development of CRC, particularly in black SA CRC patients. This will include screening demographic and histopathological data in the hope of identifying key features associated with the disease to assist with earlier detection and improvement of prognosis, particularly within this population group.

Methods {#jgh312248-sec-0006}
=======

A retrospective laboratory information system (LIS) search was conducted on all patients who had biopsy samples or colorectal resections reported by the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) branch of the National Health Laboratory Service (NHLS)/Anatomical Pathology Division, Faculty of Health Sciences, University of the Witwatersrand. Histological reports of all patients diagnosed with colorectal adenocarcinoma between 2011 and 2015 were reviewed, and data were described with respect to age, race, gender, tumor site (\[distal to the splenic flexure \[left‐sided\] and proximal to the splenic flexure \[right‐sided\]), histological subtype and grade, presence and grade of precursor lesion, invasive tumor including the presence of tumor infiltrating lymphocytes (TIL), Crohn\'s‐like inflammatory reaction (CIR), and the tumor stage (TNM). The Ethics Committee of the University of the Witwatersrand (clearance number M120994) approved this study.

*Statistical analysis* {#jgh312248-sec-0007}
----------------------

Statistical associations between race groups were investigated using Student\'s *t*‐test, Fisher\'s exact test, and Chi Square test analysis. Non‐black race patients were included in a single group, termed the "Other Race" group (White, Colored/mixed ancestry, Indian) due to small case numbers in the colored and Indian groups in comparison to the black patient group. Race was compared with age, tumor site, and morphological features as stated above. Statistical data analysis was completed using Stata Intercooled 7.0 (Stata, College Station, TX, USA) and Graphpad Prism version 7 (GraphPad Software, La Jolla, CA, USA). The results were considered statistically significant when *P* \< 0.05\* and highly significant when *P* \< 0.001\*\*\*.

Results {#jgh312248-sec-0008}
=======

A total of 665 CRC patients were diagnosed at CMJAH between 2011 and 2015, with the majority of patients being black (391/665; 59%) (Table [1](#jgh312248-tbl-0001){ref-type="table"}). Overall, the patients were predominantly male (366/665; 55%), and no variation of gender was seen among race groups. The median age of CRC was 59 years (interquartile range: 49--68). A significant association was seen between patient age and race (black *vs* other race group \[ORG\]) (median age: 56 *vs* 62 respectively), (*P* \< 0.0001). Most tumors occurred in the left colon (427/621; 69%), had an invasive adenocarcinoma subtype (596/646; 92%), were low‐grade (LG) (568/624; 91%), and presented as TNM stage III (180/350; 52%). The majority of CRC cases did not contain TILs (224/345; 65%) or a CIR (263/345; 76%), nor did they show lymphatic invasion (296/422; 70%). A minority of polyps was found (140/408; 34%), with tubular adenomas (TAs) being reported as the predominant subtype (72/140; 51%), followed by tubulovillous adenomas (TVAs) (61/140; 44%). TAs mostly displayed LG dysplasia (40/67; 60%); however, TVAs were mostly associated with high‐grade (HG) dysplasia (49/60; 82%) (*P* \< 0.0001). All the aforementioned pathological characteristics lacked any correlation with race. BRAF V600E mutations, however, exclusively occurred in ORG patients (5/21; 24%) (*P* = 0.0011).

###### 

Descriptive histopathological analysis of colorectal cancer cases diagnosed at Charlotte Maxeke Johannesburg Academic Hospital between 2011 and 2015: Black *versus* other race groups

                                                           Stratified by race groups no. of cases (%)                                                               
  ------------------------------------ ------------ -------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------------------------
  Gender                                   665                                391                                                     274                           *P* = 0.9369
  Male                                   366 (55)                           216 (55)                                                150 (55)                        
  Female                                 299 (45)                           175 (45)                                                124 (45)                        
  Age                                      660                                389                                                     271                           ***P* \< 0.0001** [**\*\*\***](#jgh312248-note-0002b){ref-type="fn"}
  Median                                    59          56[\*\*\*](#jgh312248-note-0002b){ref-type="fn"}                               62                           
  Min--Max                                15--94                             15--94                                                  25--92                         
  Mean ± SD                              57 ± 14                            55 ± 15                                                 62 ± 13                         
  P25‐P75                                 49--68                             45--65                                                  55--71                         
  95% CI                                \[56--59\]                         \[53--56\]                                              \[60--64\]                       
  ≤50 years                              184 (28)    142 (37)[\*\*\*](#jgh312248-note-0002b){ref-type="fn"}                         42 (15)                         ***P* \< 0.0001** [**\*\*\***](#jgh312248-note-0002b){ref-type="fn"}
  \>50 years                             476 (72)                           247 (63)                                                229 (85)                        
  Tumor site                               621                                368                                                     253                           *P* = 0.7634
  Left                                   427 (69)                           250 (68)                                                177 (70)                        
  Right                                  190 (30)                           115 (31)                                                75 (30)                         
  Left and right                          4 (1)                              3 (1)                                                   1 (0)                          
  Tumor subtype                            646                                380                                                     266                           *P* = 0.2878
  Invasive adenocarcinoma                596 (92)                           349 (92)                                                247 (93)                        
  Mucinous adenocarcinoma                 29 (5)                             16 (4)                                                  13 (5)                         
  Signet ring cell adenocarcinoma         20 (3)                             15 (4)                                                  5 (2)                          
  Neuroendocrine carcinoma                1 (0)                              0 (0)                                                   1 (0)                          
  Tumor grade                              624                                372                                                     252                           *P* = 0.4793
  LG                                     568 (91)                           336 (90)                                                232 (92)                        
  HG                                      56 (9)                            36 (10)                                                  20 (8)                         
  AJCC TNM staging                         350                                208                                                     142                           *P* = 0.4625
  I                                      46 (13)                            26 (13)                                                 20 (15)                         
  II                                     109 (31)                           59 (28)                                                 50 (35)                         
  III                                    180 (52)                           114 (55)                                                66 (46)                         
  IV                                      15 (4)                             9 (4)                                                   6 (4)                          
  Tumor‐infiltrating lymphocytes           345                                202                                                     143                           *P* = 0.4231
  None                                   224 (65)                           135 (67)                                                89 (62)                         
  Mild--moderate                         121 (35)                           67 (33)                                                 54 (38)                         
  Crohn\'s‐like inflamatory response       345                                202                                                     143                           *P* = 0.3077
  None                                   263 (76)                           158 (78)                                                105 (73)                        
  Mild--moderate                         82 (24)                            44 (22)                                                 38 (27)                         
  Lymphatic invasion                       422                                254                                                     168                           *P* = 0.1935
  Absent                                 296 (70)                           172 (68)                                                124 (74)                        
  Present                                126 (30)                           82 (32)                                                 44 (26)                         
  Polyps                                   408                                234                                                     174                           *P* = 0.2934
  Absent                                 268 (66)                           160 (68)                                                108 (62)                        
  Present                                140 (34)                           74 (32)                                                 66 (38)                         
  Polyp subtype                            140                                 75                                                      65                           *P* = 0.1856
  Hyperplastic polyp                      4 (3)                              1 (1)                                                   3 (5)                          
  Pseudopolyp                             2 (1)                              2 (3)                                                   0 (0)                          
  Sessile serrated adenoma                1 (1)                              0 (0)                                                   1 (1)                          
  TA                                     72 (51)                            43 (57)                                                 29 (45)                         
  TVA                                    61 (44)                            29 (39)                                                 32 (49)                         
  TA grade                                  67                                 39                                                      28                           *P* = 0.2161
  LG                                     40 (60)                            25 (65)                                                 15 (54)                         
  HG                                     27 (40)                            14 (35)                                                 13 (46)                         
  TVA grade                                 60                                 28                                                      32                           
  LG                                     11 (18)                             2 (7)                                                   8 (25)                         
  HG                                     49 (82)     25 (93)[\*\*\*](#jgh312248-note-0002b){ref-type="fn"}                          24 (75)                         
  BRAF V600E                                76                                 55                                                      21                           ***P* = 0.0011** [**\*\*\***](#jgh312248-note-0002b){ref-type="fn"}
  Wild‐type                                 71                              55 (100)                                                16 (76)                         
  Mutation                                  5                                0 (0)                            5 (24)[\*\*\*](#jgh312248-note-0002b){ref-type="fn"}  

\*Statistically significant.

\*\*\*Statistically highly significant.

AJCC, American Joint Committee on Cancer; CI, confidence interval; HG, high grade; LG, low grade; TA, tubular adenoma; TNM, tumor node metastases; TVA, tubulovillous adenoma.

Correlation between age groups, young *versus* old (≤50 *vs* \>50 years) and CRC subtype, tumor grade, TIL, and lymphatic invasion was identified (Table [2](#jgh312248-tbl-0002){ref-type="table"}). Signet ring cell carcinoma occurred at a higher frequency in the young patient group (16/183; 9%) *versus* the older patient group (4/463; 1%) (*P* = 0.0030), while a mild to moderate TIL response was more commonly found in the older patient group (95/247; 38%) than in the younger group (26/98; 27%) (*P* = 0.0450). Lymphatic invasion was associated more with younger patients (45/120; 37%) than with the older group (81/302; 27%) (*P* = 0.0341), and BRAF V600E mutations were exclusively found in older patients (5/36; 24%) *versus* younger patients (0/40; 0%) (*P* = 0.0204). No significant association was found between gender and histopathological data (Table [3](#jgh312248-tbl-0003){ref-type="table"}).

###### 

Descriptive histopathological analysis of colorectal cancer cases diagnosed at Charlotte Maxeke Johannesburg Academic Hospital between 2011 and 2015: Younger (≤50 years) *versus* older (\>50 years) patients

                                                          Stratified by age groups no. of cases (%)                                                            
  ------------------------------------ ------------ ------------------------------------------------------ --------------------------------------------------- ----------------------------------------------------------------------
  Gender                                   665                               189                                                   476                         *P* = 0.1005
  Male                                   366 (55)                          114 (60)                                             252 (53)                       
  Female                                 299 (45)                          75 (40)                                              224 (47)                       
  Age                                      660                               389                                                   271                         ***P* \< 0.0001** [**\*\*\***](#jgh312248-note-0003c){ref-type="fn"}
  Median                                    59                                41                                                   64                          
  Min--Max                                15--94                            15--50                                               51--94                        
  Mean ± SD                              57 ± 14                            40 ± 8                                               65 ± 9                        
  P25‐P75                                 49--68                            34--46                                               57--71                        
  95% CI                                \[56--59\]                        \[39--41\]                                           \[64--66\]                      
  Tumor site                               621                               179                                                   442                         *P* = 0.2999
  Left                                   426 (68)                          119 (66)                                             307 (69)                       
  Right                                  191 (31)                          60 (34)                                              131 (30)                       
  Left and right                          4 (1)                             0 (0)                                                 4 (1)                        
  Tumor subtype                            646                               183                                                   463                         ***P* \< 0.0001** [**\*\*\***](#jgh312248-note-0003c){ref-type="fn"}
  Invasive adenocarcinoma                596 (92)                          159 (87)                                             437 (94)                       
  Mucinous adenocarcinoma                 29 (5)                            8 (4)                                                21 (5)                        
  Signet ring cell adenocarcinoma         20 (3)     16 (9)[\*\*\*](#jgh312248-note-0003c){ref-type="fn"}                         4 (1)                        
  Neuroendocrine carcinoma                1 (0)                             0 (0)                                                 1 (0)                        
  Tumor grade                              624                               178                                                   446                         ***P* = 0.0030\*\***
  LG                                     568 (91)                          152 (85)                                             416 (93)                       
  HG                                      56 (9)                         26 (15)\*\*                                             30 (7)                        
  AJCC TNM staging                         350                               100                                                   250                         *P* = 0.2282
  I                                      46 (13)                            9 (9)                                                37 (15)                       
  II                                     109 (31)                          27 (27)                                               82 (33)                       
  III                                    180 (52)                          59 (59)                                              121 (48)                       
  IV                                      15 (4)                            5 (5)                                                10 (4)                        
  Tumor‐infiltrating lymphocytes           345                                98                                                   247                         ***P* = 0.0450** [**\***](#jgh312248-note-0003a){ref-type="fn"}
  None                                   224 (65)                          72 (73)                                              152 (62)                       
  Mild--moderate                         121 (35)                          26 (27)                          95 (38)[\*](#jgh312248-note-0003a){ref-type="fn"}  
  Crohn\'s‐like inflamatory response       345                                98                                                   247                         *P* = 0.1613
  None                                   263 (76)                          80 (82)                                              183 (74)                       
  Mild--moderate                         82 (24)                           18 (18)                                               64 (26)                       
  Lymphatic invasion                       422                               120                                                   302                         ***P* = 0.0341** [**\***](#jgh312248-note-0003a){ref-type="fn"}
  Absent                                 296 (70)                          75 (63)                                              221 (73)                       
  Present                                126 (30)     45 (37)[\*](#jgh312248-note-0003a){ref-type="fn"}                          81 (27)                       
  Polyps                                   408                               111                                                   297                         *P* = 0.1610
  Absent                                 268 (66)                          79 (71)                                              189 (64)                       
  Present                                140 (34)                          32 (29)                                              108 (36)                       
  Polyp subtype                            140                                32                                                   108                         *P* = 0.6291
  Hyperplastic polyp                      4 (3)                             0 (0)                                                 4 (4)                        
  Pseudopolyp                             2 (1)                             1 (3)                                                 1 (1)                        
  Sessile serrated adenoma                1 (1)                             0 (0)                                                 1 (1)                        
  TA                                     72 (51)                           18 (56)                                               54 (50)                       
  TVA                                    61 (44)                           13 (41)                                               48 (44)                       
  Polyp grade                                                                                                                                                  *P* = 0.6828
  TA                                        67                                18                                                   49                          
  LG                                     40 (60)                           10 (56)                                               30 (60)                       
  HG                                     27 (40)                            8 (44)                                               19 (40)                       
  TVA                                       60                                12                                                   48                          
  LG                                     11 (18)                            3 (25)                                               8 (17)                        
  HG                                     49 (82)                            9 (75)                                               40 (83)                       
  BRAF V600E                                76                                40                                                   36                          ***P* = 0.0204** [**\***](#jgh312248-note-0003a){ref-type="fn"}
  Wildtype                                  71                             40 (100)                                              31 (76)                       
  Mutation                                  5                               0 (0)                           5 (24)[\*](#jgh312248-note-0003a){ref-type="fn"}   

\*Statistically significant.

\*\*\*Statistically highly significant.

AJCC, American Joint Committee on Cancer; CI, confidence interval; HG, high grade; LG, low grade; TA, tubular adenoma; TNM, tumor node metastases; TVA, tubulovillous adenoma.

###### 

Descriptive histopathological analysis of colorectal cancer cases diagnosed at Charlotte Maxeke Johannesburg Academic Hospital between 2011 and 2015: Male *versus* female

                                                     Stratified by gender no. of cases (%)               
  ------------------------------------ ------------ --------------------------------------- ------------ --------------
  Gender                                   665                     366 (55%)                 299 (45%)   
  Age                                      660                        364                       296      *P* = 0.2560
  Median                                    59                        58                         60      
  Min--Max                                15--94                    15--94                     20--92    
  Mean ± SD                              57 ± 14                    56 ± 14                   59 ± 14    
  P25‐P75                                 49--68                    47--67                     51--69    
  95% CI                                \[56--59\]                \[55--58\]                 \[58--61\]  
  Tumor site                               621                        344                       277      *P* = 0.9653
  Left                                   426 (68)                  237 (69)                   189 (68)   
  Right                                  191 (31)                  105 (31)                   86 (31)    
  Left and right                          4 (1)                      2 (0)                     2 (1)     
  Tumor subtype                            646                        183                       463      *P* = 01663
  Invasive adenocarcinoma                596 (92)                  437 (87)                   267 (94)   
  Mucinous adenocarcinoma                 29 (5)                    21 (4)                     14 (5)    
  Signet ring cell adenocarcinoma         20 (3)                     4 (9)                     9 (1)     
  Neuroendocrine carcinoma                1 (0)                      1 (0)                     0 (0)     
  Tumor grade                              624                        344                       280      *P* = 01611
  LG                                     568 (91)                  308 (85)                   260 (93)   
  HG                                      56 (9)                    36 (15)                    20 (7)    
  AJCC TNM staging                         350                        100                       250      *P* = 0.2282
  I                                      46 (13)                     9 (9)                    37 (15)    
  II                                     109 (31)                   27 (27)                   82 (33)    
  III                                    180 (52)                   59 (59)                   121 (48)   
  IV                                      15 (4)                     5 (5)                     10 (4)    
  Tumor‐infiltrating lymphocytes           345                        192                       153      *P* = 0.1119
  None                                   224 (65)                  132 (69)                   92 (60)    
  Mild--moderate                         121 (35)                   60 (31)                   61 (40)    
  Crohn\'s‐like inflamatory response       345                        192                       153      *P* = 0.0569
  None                                   263 (76)                  154 (80)                   109 (71)   
  Mild--moderate                         82 (24)                    38 (20)                   44 (29)    
  Lymphatic invasion                       422                        234                       188      *P* = 0.6698
  Absent                                 296 (70)                  162 (69)                   134 (71)   
  Present                                126 (30)                   72 (31)                   54 (29)    
  Polyps                                   408                        236                       174      *P* = 0.0917
  Absent                                 268 (66)                  147 (62)                   123 (71)   
  Present                                140 (34)                   89 (38)                   51 (29)    
  Polyp subtype                            140                        89                         51      *P* = 0.4160
  Hyperplastic polyp                      4 (3)                      3 (4)                     1 (2)     
  Pseudopolyp                             2 (1)                      2 (2)                     0 (0)     
  Sessile serrated adenoma                1 (1)                      0 (0)                     1 (2)     
  TA                                     72 (51)                    43 (48)                   29 (57)    
  TVA                                    61 (44)                    41 (46)                   20 (39)    
  Polyp grade                                                                                            *P* = 0.4732
  TA                                        67                        36                         28      
  LG                                     40 (60)                    21 (58)                   17 (54)    
  HG                                     27 (40)                    15 (42)                   11 (46)    
  TVA                                       60                        41                         19      
  LG                                     11 (18)                    6 (15)                     5 (28)    
  HG                                     49 (82)                    35 (85)                   14 (72)    
  BRAF V600E                                76                        44                         32      *P* = 0.6444
  Wildtype                                  71                      42 (95)                   29 (91)    
  Mutation                                  5                        2 (5)                     3 (9)     

\*Statistically significant.

\*\*\*Statistically highly significant.

AJCC, American Joint Committee on Cancer; CI, confidence interval; HG, high grade; LG, low grade; TA, tubular adenoma; TNM, tumor node metastases; TVA, tubulovillous adenoma.

The majority of polyps were found in the left colon (81/131; 62%) and in male patients (89/140; 64%) (Tables [3](#jgh312248-tbl-0003){ref-type="table"} and [4](#jgh312248-tbl-0004){ref-type="table"}). A particular association between the side of colon and grade of TVAs was noted here (*P* = 0.0325) as left‐sided CRCs were mostly associated with HG TVAs (31/34; 91%). BRAF V600E mutations occurred exclusively in the right colon (5/34; 15%), and none were associated with left CRC tumors (0/42; 0%) (*P* = 0.0151).

###### 

Descriptive histopathological analysis of CRC cases diagnosed at Charlotte Maxeke Johannesburg Academic Hospital between 2011--2015: Left *versus* right‐sided colon cancer

                                                       Stratified by tumor site no. of cases (%)                                                              
  ------------------------------------ ---------- --------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------------------------
  Tumor site                              617                          426 (69%)                                             191 (31%)                        
  Tumor subtype                           607                             419                                                   188                           ***P* \< 0.0001** [**\*\*\***](#jgh312248-note-0005b){ref-type="fn"}
  Invasive adenocarcinoma               596 (92)                       398 (95)                                              162 (86)                         
  Mucinous adenocarcinoma                29 (5)                          9 (2)                         18 (10)[\*\*\*](#jgh312248-note-0005b){ref-type="fn"}  
  Signet ring cell adenocarcinoma        20 (3)                         12 (3)                                                 7 (4)                          
  Neuroendocrine carcinoma               1 (0)                           0 (0)                                                 1 (0)                          
  Tumor grade                             587                             399                                                   188                           *P* = 02845
  LG                                    533 (91)                       366 (92)                                              167 (89)                         
  HG                                     54 (9)                         33 (8)                                                21 (11)                         
  AJCC TNM staging                        350                             192                                                   153                           *P* = 0.6086
  I                                     46 (13)                         28 (15)                                               17 (11)                         
  II                                    109 (31)                        60 (31)                                               46 (30)                         
  III                                   180 (52)                        96 (50)                                               80 (52)                         
  IV                                     15 (4)                          8 (4)                                                10 (7)                          
  Tumor‐infiltrating lymphocytes          338                             193                                                   145                           ***P* = 0.0210** [**\***](#jgh312248-note-0005a){ref-type="fn"}
  None                                  220 (65)                       136 (70)                                               84 (58)                         
  Mild--moderate                        118 (35)                        57 (30)                          61 (42)[\*](#jgh312248-note-0005a){ref-type="fn"}    
  Crohn\'s like inflamatory response      338                             193                                                   145                           *P* = 1.0000
  None                                  258 (76)                       147 (76)                                              111 (77)                         
  Mild--moderate                        80 (24)                         46 (24)                                               34 (23)                         
  Lymphatic invasion                      417                             254                                                   163                           ***P* = 0.0009** [**\*\*\***](#jgh312248-note-0005b){ref-type="fn"}
  Absent                                293 (70)                       194 (76)                                               99 (61)                         
  Present                               123 (30)                        60 (24)                        64 (39)[\*\*\*](#jgh312248-note-0005b){ref-type="fn"}  
  Polyps                                  392                             231                                                   161                           *P* = 0.4468
  Absent                                261 (67)                       150 (65)                                              111 (69)                         
  Present                               131 (33)                        81 (35)                                               50 (31)                         
  Polyp subtype                           131                             81                                                    50                            *P* = 0.1484
  Hyperplastic polyp                     3 (2)                           3 (4)                                                 0 (0)                          
  Pseudopolyp                            2 (1)                           0 (0)                                                 2 (4)                          
  Sessile serrated adenoma               1 (1)                           0 (0)                                                 1 (2)                          
  TA                                    68 (52)                         43 (53)                                               25 (50)                         
  TVA                                   57 (44)                         35 (43)                                               22 (44)                         
  Polyp grade                             119                                                                                                                 *P* = 0.0615
  TA                                       64                             40                                                    24                            
  LG                                    38 (59)                         21 (52)                                               17 (71)                         
  HG                                    26 (41)                         19 (48)                                               7 (29)                          
  TVA                                      55                             34                                                    21                            
  LG                                    10 (18)                          3 (9)                                                7 (33)                          
  HG                                    45 (82)    31 (91)[\*](#jgh312248-note-0005a){ref-type="fn"}                          14 (67)                         
  BRAF V600E                               76                             42                                                    34                            ***P* = 0.0154** [**\***](#jgh312248-note-0005a){ref-type="fn"}
  Wildtype                                 71                          42 (100)                                               29 (85)                         
  Mutation                                 5                             0 (0)                           5 (15)[\*](#jgh312248-note-0005a){ref-type="fn"}     

\*Statistically significant.

\*\*\*Statistically highly significant.

AJCC, American Joint Committee on Cancer; CI, confidence interval; CRC, colorectal cancer; HG, high grade; LG, low grade; TA, tubular adenoma; TNM, tumor node metastases; TVA, tubulovillous adenoma.

Discussion {#jgh312248-sec-0009}
==========

The focus of this study was to ascertain common features, particularly demographic and histopathological characteristics, associated with black patients to assist in the earlier detection and better management of the disease. Although this study demonstrated no significant differences between male and female patients, black *versus* ORG and younger *versus* older patient groups illustrated significant differences in a number of parameters.

A total of 665 CRC patients were diagnosed at CMJAH over a 5‐year period, from 2011 to 2015. Patients were predominantly male and black, with a considerable proportion being young. The median age of black patients compared to ORG patients (56 *vs* 62 years, respectively) was significantly younger. The data confirmed local and international reports regarding male *versus* female ratios (55 *vs* 45%, respectively),[1](#jgh312248-bib-0001){ref-type="ref"}, [5](#jgh312248-bib-0005){ref-type="ref"} with black patients showing an earlier age of onset in comparison to the white group.[7](#jgh312248-bib-0007){ref-type="ref"}, [15](#jgh312248-bib-0015){ref-type="ref"} In comparison, in African Americans (AA), the median age of onset in males and females were reported to be 66 and 70 years, respectively, compared to 72 and 77 in white men and women, respectively.[16](#jgh312248-bib-0016){ref-type="ref"} In this SA cohort, the median age for male and female black patients was 55 and 56 years, respectively, *versus* 62 and 65 years for males and females of ORG, respectively. The median age for white male and female patients (separated from Indian and colored or mixed race) remained 62 and 65 years, respectively. These data showed that SA black and white patients are at least 10 years younger in comparison to U.S. AA and U.S. white patients.

The frequency of young black patients younger than 50 years of age in this cohort (37%) was similar to that of young black SA CRC patients in the NCR 2014 report (32%). The majority of tumors occurred in the left colon, had an invasive adenocarcinoma subtype, LG tumors, and presented at an advanced TNM stage (III and IV) These findings were in concordance with international published data that reported an approximate 70% occurrence of left‐sided CRC, with about 90% being of an invasive adenocarcinoma subtype, that was moderately to well differentiated, with approximately 50--60% of CRC cases presenting at a more advanced stage.[17](#jgh312248-bib-0017){ref-type="ref"}, [18](#jgh312248-bib-0018){ref-type="ref"} Male and female patients had equal frequencies for tumor site (69% left‐sided *vs* 31% right‐sided). This finding is contrary to other studies showing right‐sided colon cancer to be increased in female patients and left‐sided CRC to be increased in males.[19](#jgh312248-bib-0019){ref-type="ref"}

In the present analysis, with regard to polyps, conventional adenomas (TA, TVA, and villous adenomas \[VAs\]) are mostly found in the left colon,[20](#jgh312248-bib-0020){ref-type="ref"} with TAs described as the predominant subtype (80%), TVAs accounting for 10--20%, and VAs less than 5%.[21](#jgh312248-bib-0021){ref-type="ref"}, [22](#jgh312248-bib-0022){ref-type="ref"}, [23](#jgh312248-bib-0023){ref-type="ref"} In this study, polyps were found in 34% (140/408) of cases, with only 1% being sessile serrated adenoma (SSA), 4% hyperplastic polyps (HPs), 51% TAs, and 44% TVAs. TAs were mostly associated with LG dysplasia (60%), and TVAs that also occurred at a considerably high frequency than that stated in literature were mostly associated with HG dysplasia (83%) (*P* \< 0.0001). The size of the adenomatous polyp (AP) was not recorded in the majority of reports, only the quantity of APs and grade of dysplasia. This study showed no association of APs with race, gender, or patient age; however, HG TVAs were more commonly found in the left colon (*P* = 0.0325). The transition from LG APs to more advanced APs or CRC takes approximately 3 years, suggesting that frequent surveillance colonoscopies for the earlier detection of CRC would benefit patients. Guidelines indicate repeat surveillance every 5--10 years for 1--2 small TAs (\<1 cm) with LG dysplasia, and where 3--10 large APs are found (≥1 cm) or in those with HG dysplasia or with villous features, colonoscopy should be performed every 3 years.[20](#jgh312248-bib-0020){ref-type="ref"}, [23](#jgh312248-bib-0023){ref-type="ref"}

The literature indicates that AA patients are more likely to have right‐sided tumors than left.[15](#jgh312248-bib-0015){ref-type="ref"}, [24](#jgh312248-bib-0024){ref-type="ref"}, [25](#jgh312248-bib-0025){ref-type="ref"} This SA study, however, showed no relationship between race and tumor site. BRAF V600E mutational analysis was carried out in 76 patients, and an association was only found in older white patients with right‐sided colon cancers, possibly indicating development via the microsatellite instability CRC pathway.

CRC research in AA patients has demonstrated higher incidence and mortality rates, earlier age of diagnosis, more advanced stage of the disease, and a greater proportion of right‐sided colon cancers in comparison to other ethnic groups. This has led American professional societies to change guidelines, recommending colonoscopy screening by 45 instead of 50 years of age, which has led to a great reduction in CRC incidence in this population group.[26](#jgh312248-bib-0026){ref-type="ref"} Although statistically significant differences concerning stage and tumor site were not seen when comparing black *versus* ORG patients, later stage of disease and earlier age of onset in black patients remained significant factors, and a policy recommending earlier screening in this population group should be considered to reduce incidence rates.

In conclusion, this study shows that black SA CRC patients most likely follow a different carcinogenic pathway in comparison to other SA ethnic groups due to earlier age of onset. Black SA patients also seem to present at least a decade earlier when comparing Africans found in the Western world, with more left‐sided CRC occurring in SA patients compared to a right‐sided CRC association seen in AAs. Moreover, a lack of BRAF V600E mutation in the black SA CRC population in this study suggests that there is a different carcinogenic pathway in black SA CRC patients compared to other ethnic groups, which still needs to be evaluated in a larger cohort of patients. TVAs found at a frequent rate across different ethnic groups in SA patients could possibly suggest a dominant adenocarcinoma sequence in the development of the disease. The initiation of earlier screening and more frequent surveillance policies in black SA patients could possibly result in better management of the disease. Further epidemiological research linked to molecular characterization in SA population groups is still needed to assist in determining the underlying cause and designing more personalized treatment strategies for better management of the disease.
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